NASDAQ:EXEL

Exelixis (EXEL) Stock Price, News & Analysis

Exelixis logo
$65.71 -2.58 (-3.78%)
As of 03:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Exelixis Stock (NASDAQ:EXEL)

Advanced

Key Stats

Today's Range
$65.36
▼
$68.50
50-Day Range
$56.12
▼
$72.75
52-Week Range
$39.71
▼
$73.69
Volume
1.79 million shs
Average Volume
2.62 million shs
Market Capitalization
$16.03 billion
P/E Ratio
19.65
Dividend Yield
N/A
Price Target
$58.62
Consensus Rating
Hold

Company Overview

Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies.

Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer. Exelixis also develops additional targeted therapies and investigates new uses for its medicines.

Exelixis commercializes products in the United States and works with pharmaceutical partners to make certain medicines available in other markets. The company is led by President and Chief Executive Officer Michael M. Morrissey, who has held the role since 2016.

AI Generated. May Contain Errors.

Exelixis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

EXEL MarketRank™: 
2.264485344235 of 5 stars

Exelixis scored higher than 45% of companies evaluated by MarketBeat, and ranked 1195th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exelixis has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on 1 strong buy rating, 6 buy ratings, 9 hold ratings, and 1 sell rating.

  • Downside Risk

    Exelixis has a consensus price target of $58.62, representing about 11.0% downside from its current price of $65.87.

  • Amount of Analyst Coverage

    Exelixis has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Exelixis' stock forecast and price target.
  • Earnings Growth

    Earnings for Exelixis are expected to grow by 11.11% in the coming year, from $3.42 to $3.80 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exelixis is 19.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.78.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exelixis is 19.72, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.98.

  • Price to Earnings Growth Ratio

    Exelixis has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Exelixis has a P/B Ratio of 8.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.77% of the float of Exelixis has been sold short.
  • Short Interest Ratio / Days to Cover

    Exelixis has a short interest ratio ("days to cover") of 11.71, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Exelixis has recently decreased by 6.30%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Exelixis does not currently pay a dividend.

  • Dividend Growth

    Exelixis does not have a long track record of dividend growth.

  • News Sentiment

    Exelixis has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Exelixis this week, compared to 8 articles on an average week.
  • Search Interest

    Only 12 people have searched for EXEL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exelixis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.60% of the stock of Exelixis is held by insiders.

  • Percentage Held by Institutions

    85.27% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exelixis' insider trading history.
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EXEL Stock News Headlines

Should You Buy Exelixis Stock For Its Cash?
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
Exelixis Eyes Turning Point as Colorectal Cancer Drug Decision Nears
Laboratory bench with pipettes, microplates, a centrifuge, analytical balance, and chromatography equipment.
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock (EXEL)
Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.
See More Headlines

EXEL Stock Analysis - Frequently Asked Questions

Exelixis' stock was trading at $43.83 on January 1st, 2026. Since then, EXEL stock has increased by 50.3% and is now trading at $65.8690.

Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings data on Thursday, October, 29th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.89 by $0.05. Exelixis's quarterly revenue was up 10.2% compared to the same quarter last year.
Read the conference call transcript
.

Exelixis' top institutional shareholders include State Street Corp (4.31%), First Trust Advisors LP (1.16%), Stephens Investment Management Group LLC (1.06%) and Allspring Global Investments Holdings LLC (1.00%). Insiders that own company stock include David Edward Johnson, Stelios Papadopoulos, Christopher J Senner, Jeffrey Hessekiel, Dana Aftab, Amy C Peterson, Patrick J Haley, Jack L Wyszomierski, George Poste, Brenda Hefti, Brenda Hefti, Maria C Freire, Maria C Freire, Alan M Garber, Tomas J Heyman, Bob Oliver, Sue Gail Eckhardt and Mary C Beckerle.
View institutional ownership trends
.

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exelixis investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Bristol Myers Squibb (BMY), Gilead Sciences (GILD) and Tesla (TSLA).

Company Calendar

Last Earnings
10/29/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EXEL
CIK
939767
Employees
1,077
Year Founded
1994

Price Target and Rating

High Price Target
$78.00
Low Price Target
$41.00
Potential Upside/Downside
-10.8%
Consensus Rating
Hold
Rating Score (0-4)
2.41
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.34
Trailing P/E Ratio
19.65
Forward P/E Ratio
17.29
P/E Growth
1.77
Net Income
$782.57 million
Net Margins
35.45%
Pretax Margin
42.69%
Return on Equity
45.54%
Return on Assets
33.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.21
Quick Ratio
3.14

Sales & Book Value

Annual Sales
$2.50 billion
Price / Sales
6.42
Cash Flow
$2.90 per share
Price / Cash Flow
22.63
Book Value
$7.52 per share
Price / Book
8.74

Miscellaneous

Outstanding Shares
244,011,000
Free Float
237,667,000
Market Cap
$16.03 billion
Optionable
Optionable
Beta
0.45

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:EXEL) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners